COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-β, IL-10 and Ki67

Cancer Epidemiology

Volumn 34, Issue 3, 2010, Pages 316-322

  Richardsen, Elin ^a   Uglehus, Rebecca Dale ^a   Due, Jan ^a,b   Busch, Christer ^a,c   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

COX 2; Digital video analysis; Immunohistochemistry; Ki67; Metastases; Prognosis; Prostate cancer; TGF

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 10; KI 67 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BLADDER METASTASIS; CANCER MORTALITY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE DURATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RECTUM CANCER; SEMINAL VESICLE DISEASE; TUMOR CELL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CYCLOOXYGENASE 2; HUMANS; INTERLEUKIN-10; KI-67 ANTIGEN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECTAL NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; URINARY BLADDER NEOPLASMS;

EID: 77952236681     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.03.019     Document Type: Article

References (39)

1. Hussain T., Gupta S., and Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191 (2003) 125-135
2. Steiner M.S., Zhou Z.Z., Tonb D.C., and Barrack E.R. Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 135 5 (1994) 2240-2247
3. Barrack E.R. TGFβ in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31 (1997) 61-70
4. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30 1 (2000) 3-21
5. Dandekar D.S., and Lokeshwar B.I. Inhibition of cyclooxygenase (COX)-2 expressions by the-inducible COX-2 antisense CDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10 (2004) 8037-8047
6. Wu T. Cyclooxygenase-2 and prostaglandin signalling in cholangiocarcinoma. Biochem Biophys Acta 1755 (2005) 135-150
7. Lagarde S.M., Kate F.J.W., Richel D.J., Offerhaus G.J.A., and Lanschot J.J.B. Molecular prognostic factors in adenocarcinoma of esophagus and gastroesophageal junction. Ann Surg Oncol 14 2 (2006) 977-991
8. Fournier D.B., and Gordon G.B. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl 34 (2000) 97-102
9. Gupta R.A., and Dubios R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1 (2001) 11-21
10. Fujita H., Koshida K., Keller E., Takahashi Y., Yoshimito T., Namiki M., et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53 (2002) 232-240
11. Gupta S., Strivastav M., Bostwick D.G., and Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42 (2000) 73-78
12. Zha S., Gage W.R., Suvageot J., Saria E.A., Putzi M.J., Ewing C.M., et al. Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61 (2001) 8617-8623
13. Bierie B., and Moses H.L. TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6 (2006) 506-520
14. Oft M., Heider K.H., and Beug H. TGF-β signalling is necessary for carcinoma cell invasiveness and metastases. Curr Biol 8 (1998) 1243-1252
15. Perry K.T., Anthony C.T., and Steiner M. Immunohistochemical localization of TGF-β1, TGF-β2 and TGF-β3 in normal and malignant human prostate. Prostate 33 (1997) 133-140
16. Steiner M.S., Zhou Z.Z., Tonb D.C., and Barrack E.R. Expression of transforming growth factorβ1 in prostate cancer. Endocrinology 136 5 (1994) 2240-2247
17. Levy L., and Hill C.S. Alteration in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17 (2006) 41-58
18. Brown J.R., and DuBois R.N. Cyclooxygenase-2 in lung carcinogenesis and chemoprevention. Chest 125 (2004) 134S-140S
19. Howell W.M., and Rose-Zerilli M.J. Cytokine polymorphisms, cancer susceptibility, and prognosis. J Nutr 137 (2007) 194S-199S
20. Huang S., Ullrich S.E., and Bar-Eli M. Regulation of tumor growth and metastases by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19 (1999) 97-703
21. Fiella X., Alcover J., Zarco M.A., Beardo P., Molina R., and Ballesta A.M. Analysis of Type T1 and T2 cytokines in patients with prostate cancer. Prostate 44 (2000) 271-274
22. Michaud D.S., Daugherty S.E., Berndt S.I., Platz E.A., Yeager M., Crawford E.D., et al. Genetic polymorphism of interleukin-1B (IL-1B), Il-6, IL-8 and IL-10 and risk of prostate cancer. Cancer Res 66 8 (2006) 4525-4530
23. Eder T., Mayer R., Langsenlehner U., Renner W., Krippl P., Wascher T.C., et al. Interleukin-10 (ATA) promoter haplotype and prostate cancer risk: a population-based study. Eur J Cancer 43 (2007) 472-475
24. Sun J., Hedelin M., Zheng S.L., Adami H.O., Bensen J., Augustsson-Balter K., et al. Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 13 (2004) 1677-1679
25. Cowen D., Troncoso P., Khoo V.S., Zagars G.K., Von Eschenbach A.C., Meistrich M.L., et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8 (2002) 1148-1154
26. Bubendorf L., Saunders M.I., Dische S., Daley F.M., Roinson B.M., Martindale C.A., et al. Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178 (1996) 437-441
27. Bettencourt M.C., Bauer J.J., Sesterhenn I.A., Mostofi F.K., McLeod D.G., and Moul J.W. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 56 (1996) 1064-1068
28. Khor L.Y., Bae K., Paulus R., Al-Saleem T., Hammond M.E., Grignon D.J., et al. MDM2 and Ki-67 predict for distant metastasis and mortality in men with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol 19 27 (2009) 3177-3184
29. Kirschenbaum A., Liu X., Yao S., and Levine A.C. The role of cyclooxygenase-2 in prostate cancer. Urology 58 (2001) 127-131
30. Wang W., Bergh A., and Damber J.E. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 11 9 (2005) 3250-3256
31. Izawa J.I., and Dinney C.P.N. The role of angiogenesis in prostate and other urologic cancers: a review. CMAJ 164 5 (2001) 662-670
32. Khor L.Y., Bae K., Pollack A., Hammond E.M.H., Grignon D.J., Venkatesan V.M., et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8 (2007) 912-920
33. Sooriakumaran P., Coley H.M., Fox S.B., Macanas-Pirard P., Lovell D.P., Henderson A., et al. A randomized controlled trial investigation the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 29 5 (2009) 1483-1488
34. Baselga J., Rothenberg M.L., Tabernero J., Seoane J., Daly T., Cleverly A., et al. TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers 13 2 (2008) 217-236
35. Shappell S.B., Manning S., Boeglin W.E., Guan Y.F., Roberts R.L., Davis L., et al. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 3 (2001) 287-303
36. Pollack A., DeSilvio M., Khor L.Y., Al-Saleem, Hammond M.E., Venkatesan V., et al. Ki-67 staining is a strong predictor of distant metastases and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: radiation therapy oncology group trial 92-02. J Clin Oncol 22 11 (2004) 2133-2140
37. De Boer W.I., Hiemstra P.S., Sont J.K., de Heer E., Rabe K.F., Van Krieken J.H.J.M., et al. Image analysis and quantification in lung tissue. Clin Exp Allergy 31 (2001) 504-508
38. Sullivan P., Stephens D., Ansari T., Costello J., and Jeffrey P. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Respir 12 (1998) 811-815
39. Faul J.L., Demers E.A., Burke C.M., and Poulter L.W. The reproducibility of repeated measures of airway inflammation in stable atopic asthma. Am J Respir Crit Care Med 160 (1999) 1457-1461